Journal
NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-019-12771-9
Keywords
-
Categories
Funding
- National Basic Research Plan of China [2018YFA0208903]
- National Natural Science Foundation of China [81972894, 81673364]
- Ministry of Science and Technology of the People's Republic of China [2017ZX09101001006]
- Fundamental Research Funds for the Central Universities [2632018ZD13]
- Six Talents Summit Program of Jiangsu Province
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
One of the main challenges for immune checkpoint blockade antibodies lies in malignancies with limited T-cell responses or immunologically cold tumors. Inspired by the capability of fever-like heat in inducing an immune-favorable tumor microenvironment, mild photothermal therapy (PTT) is proposed to sensitize tumors to immune checkpoint inhibition and turn cold tumors hot. Here we present a combined all-in-one and all-in-control strategy to realize a local symbiotic mild photothermal-assisted immunotherapy (SMPAI). We load both a near-infrared (NIR) photothermal agent IR820 and a programmed death-ligand 1 antibody (aPD-L1) into a lipid gel depot with a favorable property of thermally reversible gel-to-sol phase transition. Manually controlled NIR irradiation regulates the release of aPD-L1 and, more importantly, increases the recruitment of tumor-infiltrating lymphocytes and boosts T-cell activity against tumors. In vivo antitumor studies on 4T1 and B16F10 models demonstrate that SMPAI is an effective and promising strategy for treating cold tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available